Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data
-
Requisite clinical responses achieved in cohort 1 of Part A (1st line NSCLC) of TACTI-002 Phase II clinical trial to allow for recruitment of cohort 2
-
Recruitment of cohort 2 of Part A of TACTI-002, additional 19 patients, will begin shortly
-
Recruitment of the first cohorts of parts B and C continues
-
Data from the ongoing TACTI-002 Phase II clinical trial will be presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November 2019
SYDNEY, AUSTRALIA – September 26, 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or the “Company”),
a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces that the requisite number of predefined patient responses has been
exceeded in cohort 1 of Part A (first line non-small cell lung cancer (NSCLC)) of the TACTI-002 Phase II clinical trial based on an interim analysis. This allows the Company to proceed with the recruitment of an additional 19 patients for cohort 2 of Part A of the study. TACTI-002 is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada).
For further information please download the attached PDF:
Download this document
